• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

EFPIA: TTIP Must Go Further to Tackle Regulatory Barriers


May 25, 2016.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that while it welcomes the publication of the European Commission’s negotiating proposal on regulatory cooperation in pharmaceuticals – and its efforts to increase transparency in the TTIP negotiations – it "fail[s] to see additional and necessary regulatory proposals that would allow TTIP to deliver ambitious outcomes once it enters into force".

EFPIA noted the good progress made to date in advancing a mutual recognition agreement on Good Manufacturing Practice (GMP) inspections, but said it hoped to see a broader range of concrete deliverables, such as in the area of paediatric medicines.

It is important to further tackle "unnecessary regulatory barriers and administrative burdens within the transatlantic pharmaceutical marketplace if TTIP is to be considered an ambitious agreement," EFPIA added.

Related Videos